CNSY PLUS THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, PLUS THERAPEUTICS INC reported revenue of $411K (down 70.4% from a year earlier), net income of −$9.01M and diluted EPS of −$1.31; over the last four quarters revenue was $4.20M and net income −$26.1M; for the fiscal year ended December 2025 revenue was $5.21M, down 10.5% on the year before.

CNSY annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $5.21M, gross profit n/a, operating income −$15.3M, net income −$22.4M (margin -429.4%), EPS −$0.29
• Fiscal year ended Dec 2024: revenue $5.82M, gross profit n/a, operating income −$14.7M, net income −$13.0M (margin -222.8%), EPS −$2.34
• Fiscal year ended Dec 2023: revenue $4.91M, gross profit n/a, operating income −$13.3M, net income −$13.3M (margin -271.0%), EPS −$4.24
• Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$19.7M, net income −$20.3M (margin n/a), EPS −$11.58
• Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$12.5M, net income −$13.4M (margin n/a), EPS −$1.11

CNSY quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $411K (down 70.4% year over year), net income −$9.01M, EPS −$1.31
• Quarter ended Mar 31, 2026: revenue $1.03M (down 2.9% year over year), net income −$6.95M, EPS −$1.05
• Quarter ended Dec 31, 2025 (from the annual report): revenue $1.37M (down 3.2% year over year), net income −$5.71M, EPS $29.77
• Quarter ended Sep 30, 2025: revenue $1.40M (down 4.1% year over year), net income −$4.42M, EPS −$0.04
• Quarter ended Jun 30, 2025: revenue $1.39M (up 8.7% year over year), net income $5.15M, EPS −$0.16
• Quarter ended Mar 31, 2025: revenue $1.06M (down 36.9% year over year), net income −$17.4M, EPS −$29.86
• Quarter ended Dec 31, 2024 (from the annual report): revenue $1.41M, net income −$3.90M, EPS −$0.51
• Quarter ended Sep 30, 2024: revenue $1.46M, net income −$2.87M, EPS −$0.37
• Quarter ended Jun 30, 2024: revenue $1.28M, net income −$2.94M, EPS −$0.71
• Quarter ended Mar 31, 2024: revenue $1.68M, net income −$3.26M, EPS −$0.75
• Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$3.81M, EPS −$0.58
• Quarter ended Sep 30, 2023: revenue n/a, net income −$3.22M, EPS −$1.00
• Quarter ended Jun 30, 2023: revenue n/a, net income −$1.48M, EPS −$0.59
• Quarter ended Mar 31, 2023: revenue n/a, net income −$4.81M, EPS −$2.07
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$5.66M, EPS −$4.98
• Quarter ended Sep 30, 2022: revenue n/a, net income −$5.22M, EPS −$2.85
• Quarter ended Jun 30, 2022: revenue n/a, net income −$5.28M, EPS −$3.56
• Quarter ended Mar 31, 2022: revenue n/a, net income −$4.12M, EPS −$0.19
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$4.16M, EPS −$0.25
• Quarter ended Sep 30, 2021: revenue n/a, net income −$3.72M, EPS −$0.28

CNSY cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$20.8M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$10.6M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$12.9M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$13.0M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$10.3M, share buybacks n/a

CNSY balance sheet

• Jun 30, 2026: cash $2.37M, total assets $14.0M, total liabilities $8.57M, shareholders' equity $5.46M
• Mar 31, 2026: cash $3.02M, total assets $19.9M, total liabilities $7.96M, shareholders' equity $12.0M
• Dec 31, 2025: cash $4.26M, total assets $16.3M, total liabilities $12.3M, shareholders' equity $4.00M
• Sep 30, 2025: cash $13.3M, total assets $18.7M, total liabilities $13.6M, shareholders' equity $5.05M
• Jun 30, 2025: cash $2.23M, total assets $10.4M, total liabilities $7.32M, shareholders' equity $3.03M
• Mar 31, 2025: cash $9.87M, total assets $12.1M, total liabilities $35.7M, shareholders' equity −$23.6M
• Dec 31, 2024: cash $76.0K, total assets $6.63M, total liabilities $15.6M, shareholders' equity −$8.95M
• Sep 30, 2024: cash $1.22M, total assets $6.98M, total liabilities $12.2M, shareholders' equity −$5.17M

What is CNSY's revenue?

PLUS THERAPEUTICS INC reported $4.20M of revenue over its last four quarters, through June 30, 2026.

Is CNSY profitable?

No. PLUS THERAPEUTICS INC lost $26.1M over the last four quarters.

What is CNSY's EPS?

Diluted earnings per share over the last four quarters were $27.37; −$1.31 in the latest quarter.

CNSY ownership and insider trades · All stocks